The company is investing billions of dollars to construct a European biosimilar hub capable of supporting the rapid expansion ...

Bristol Myers Squibb is positioning arlo-cel for quadruple-class exposed patients, which could help reduce competition with ...

As geopolitical tensions between the U.S. and China grow increasingly complicated, here are five alternative territories for ...

Months before the current biotech IPO boom, public investors began a more confident trek back into the sector, signaling the ...

Watch this discussion on how GLP-1 drugs for obesity are changing the shape of U.S. healthcare. From direct-to-consumer portals to pharmacy deals, how these drugs reach patients is changing—and ...

BioSpace is launching an IPO dashboard to help the industry keep tabs on U.S. biotechs that have taken the public plunge in 2026. There’s no doubt that biotech IPOs are back. After a prolonged ...

Inhibrx CEO Mark Lappe was particularly keen on INBRX-106’s performance in patients with HPV-positive disease and sees a ...

Structure Therapeutics’ oral GLP-1 candidate aleniglipron showed 72-week efficacy “in line” with Novo Nordisk’s oral Wegovy, ...

After the failure of Novo Nordisk’s IL-6 inhibitor ziltivekimab sent waves through the industry, the company has terminated ...

The approval opens up a “modest” market for AstraZeneca’s Etcamah, according to Leerink analysts, who nevertheless looked ...

BrainChild Bio’s lead asset BCB-276 is in pivotal development for diffuse intrinsic pontine glioma, a rare and fatal brain tumor that affects around 300 children in the U.S. every year.

Belgium and the Netherlands have built some of Europe's strongest life sciences ecosystems, powered by leading research ...